<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429583</url>
  </required_header>
  <id_info>
    <org_study_id>CRI-0844</org_study_id>
    <secondary_id>U19AI111825</secondary_id>
    <nct_id>NCT02429583</nct_id>
  </id_info>
  <brief_title>Effects of Persistent Innate Immune Activation on Vaccine Efficacy</brief_title>
  <official_title>Effects of Persistent Innate Immune Activation on Vaccine Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rockefeller University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the effects of chronic HCV infection and corresponding innate
      immune activation on the immune response to HBV vaccination. We will recruit chronic HCV
      patients and healthy control patients for HBV vaccination. We will use RNA Sequencing
      (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all
      genes, to determine patients' innate immune status, and learn how this innate immune
      signature is related to HBV vaccine response. We will then explore the mechanisms by which
      chronic HCV infection affects different immune cells and functions that are known to be
      important for an effective HBV vaccine response. These studies will enhance our understanding
      of the immune effects of chronic viral infection, establish factors that determine effective
      vaccine responses, and help guide vaccination strategies for HCV patients and other
      individuals with chronic inflammatory disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vaccines have been responsible for preventing millions of deaths and extending the average
      human lifespan. Effective vaccines stimulate the cells of the immune system to activate genes
      and associated functions that bring about protective immunity. If we can better understand
      the factors that influence vaccine success versus failure, we may be able to improve current
      vaccines and/or develop new vaccines against prevalent infectious diseases.

      Certain groups of people do not respond well to particular vaccines. For example, vaccines
      can be less effective in immunocompromised patients, elderly individuals, and people with
      chronic inflammatory diseases. Often it is these groups of people that have the greatest need
      for protection against infectious disease.

      People chronically infected with hepatitis C virus (HCV) are at increased risk of serious
      liver disease. As a result, they should receive the hepatitis B virus (HBV) vaccine, which
      can protect them from infection by HBV, another virus that targets the liver. However, people
      chronically infected with HCV do not respond to the HBV vaccine as effectively as healthy
      people without HCV. Chronic HCV infection is not thought to cause general problems with the
      immune system, and the reasons for this poor vaccine response are poorly understood. Previous
      work has shown that chronic HCV infection leads to production of chemical (&quot;innate immune&quot;)
      signals that can affect function of the immune system, but it is currently unknown how this
      might impact vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll sufficient subjects
  </why_stopped>
  <start_date type="Actual">May 8, 2015</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HBV Vaccine Response Versus Non-response Status</measure>
    <time_frame>8 months</time_frame>
    <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</measure>
    <time_frame>8 months</time_frame>
    <description>ELISPOT assays will measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</measure>
    <time_frame>8 months</time_frame>
    <description>Flow cytometry assays measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</measure>
    <time_frame>8 months</time_frame>
    <description>Isolated from patient PBMCs measured at 8 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</measure>
    <time_frame>8 months</time_frame>
    <description>Isolated from patient PBMCs measured at 8 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Recombivax in HCV infected individuals</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombivax vaccine administered IM to HCV-infected individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Recombivax in healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Recombivax vaccine administered IM to healthy individuals</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombivax</intervention_name>
    <description>Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
    <arm_group_label>Recombivax in HCV infected individuals</arm_group_label>
    <arm_group_label>Recombivax in healthy volunteers</arm_group_label>
    <other_name>Hepatitis B vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing to receive three doses of an FDA-approved Hepatitis B vaccine

          -  Volunteer chronically infected with HCV (as demonstrated by serology and/or viral load
             laboratory studies)

          -  Healthy volunteer without significant medical problems

        Exclusion Criteria:

          -  Received any vaccine within a month prior to study vaccine

          -  Positive serum antibody against Hep B surface antigen and/or core Hep B core antigen

          -  HIV positive

          -  For HCV-negative, healthy volunteers: History of HCV infection or positive HCV
             antibody test

          -  Participation in another clinical study of an investigational product currently or
             within the past 90 days, or expected participation during this study

          -  In the opinion of the investigator, the volunteer is unlikely to comply with the study
             protocol

          -  Any clinically significant abnormality or medical history or physical examination
             including history of immunodeficiency or autoimmune disease (in addition to HCV
             infection, for HCV group)

          -  Currently taking systemic steroids or other immunomodulatory medications including
             anticancer medications and antiviral medications

          -  Any clinically significant acute or chronic medical condition requiring care by a
             primary care provider (e.g., diabetes, coronary artery disease, rheumatologic illness,
             malignancy, substance abuse) that, in the opinion of the investigator, would preclude
             participation

          -  Unable to continue participation for 156 weeks

          -  History of previous Hepatitis B vaccination(s)

          -  Male or female &lt; 18 and &gt; 62 years of age

          -  Is pregnant or lactating

          -  History of Hepatitis B infection

          -  Clinical, laboratory, or biopsy evidence of cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Rice, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Rockefeller University Center for Clinical and Translational</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rockefeller University Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <results_first_submitted>February 3, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 4, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rockefeller University</investigator_affiliation>
    <investigator_full_name>Charles Rice</investigator_full_name>
    <investigator_title>Head of Laboratory of Virology and Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02429583/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="P2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only 4 participants completed the study. One HCV infected individual enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="B2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="60" upper_limit="60"/>
                    <measurement group_id="B2" value="44" lower_limit="42" upper_limit="49"/>
                    <measurement group_id="B3" value="48" lower_limit="42" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HBV Vaccine Response Versus Non-response Status</title>
        <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>HBV Vaccine Response Versus Non-response Status</title>
          <description>Titers of anti-hepatitis B surface antigen antibody measured at 8 months
Luminex assay for multiplex cytokine/chemokine panel measured at 8 months RNA-Seq with analysis focus on curated ISG list measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</title>
        <description>ELISPOT assays will measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Functional Status of Anti-HBsAg Antibody-producing B Cells Post-vaccination Doses Over Time</title>
          <description>ELISPOT assays will measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</title>
        <description>Flow cytometry assays measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Functional Status of HBsAg-specific CD4+ &quot;Helper&quot; T Cells</title>
          <description>Flow cytometry assays measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</title>
        <description>Isolated from patient PBMCs measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Response of Monocytes Stimulated ex Vivo With Vaccine Antigen and/or Adjuvant</title>
          <description>Isolated from patient PBMCs measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</title>
        <description>Isolated from patient PBMCs measured at 8 months</description>
        <time_frame>8 months</time_frame>
        <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
        <group_list>
          <group group_id="O1">
            <title>Recombivax in HCV Infected Individuals</title>
            <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Recombivax in Healthy Volunteers</title>
            <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Gene Expression Profile of Conventional Dendritic Cells Measured by RNA-Seq</title>
          <description>Isolated from patient PBMCs measured at 8 months</description>
          <population>The data was not collected and the analysis was not completed for this study due to insufficient enrollment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 weeks</time_frame>
      <desc>Adverse event information was collected from both arms of the study (3 healthy volunteers and 1 HCV infected individual)</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombivax in HCV Infected Individuals</title>
          <description>Recombivax vaccine administered IM to HCV-infected individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
        <group group_id="E2">
          <title>Recombivax in Healthy Volunteers</title>
          <description>Recombivax vaccine administered IM to healthy individuals
Recombivax: Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cold Like Symptoms</sub_title>
                <description>Volunteer complained of &quot;cold-like&quot; symptoms (headache, sneezing, scratchy throat) without cough or fever.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Patient Stubbed Toe</sub_title>
                <description>Volunteer reported that he stubbed the great toe of his left foot on 08/19/2015 resulting in moderate pain and discomfort</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Pain at Injection Site</sub_title>
                <description>Volunteer experienced mild tenderness at the right upper arm vaccination site twenty minutes after receiving his first Hepatitis B vaccination which resolved by next day</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aileen O'Connell, Laboratory Manager</name_or_title>
      <organization>The Rockefeller University</organization>
      <phone>212-327-7047</phone>
      <email>aoconnell@rockefeller.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

